Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1995 Jun 1;181(6):2037–2048. doi: 10.1084/jem.181.6.2037

Polymorphism of human minor histocompatibility antigens: T cell recognition of human minor histocompatibility peptides presented by HLA- B35 subtype molecules

PMCID: PMC2192060  PMID: 7759996

Abstract

To investigate the polymorphism of human minor histocompatibility (mH) antigens, PBLs from 23 Japanese individuals and 25 German individuals with HLA-B35 were studied by using four human mH antigen-specific, HLA- B35-restricted CTL clones. The CTL clones killed PHA-stimulated PBLs from all 23 Japanese individuals. On the other hand, they killed the PHA-stimulated PBLs from 19 of 25 German individuals and partially killed the PHA-stimulated PBLs from three German individuals (CTL weakly sensitive cell line); those from another three individuals (CTL- resistant cell line) were not killed by the CTL clones. All of three CTL weakly sensitive cell lines carry HLA-B*3503 molecules, whereas the three CTL-resistant cell lines carry HLA-B*3502, B*3507, and B*3508 molecules. The cytotoxicity of the CTL clones for three CTL weakly sensitive cell lines was enhanced by stimulation of human mH peptides isolated from HLA-B*3501 molecules purified from C1R-B*3501 cells. Small amounts of human mH peptides were isolated from B*3503 molecules purified from these three CTL weakly sensitive cell lines. Taken together, these results indicate that weak recognition by the CTL clones of three CTL weakly sensitive cell line results from a small amount of the human mH peptides presented by B*3503 molecules. The CTL- resistant cell line carrying B*3507 loaded with the human mH peptides was killed by four CTL clones, whereas the cell lines carrying B*3502 or B*3508 loaded with the peptides were not. The human mH peptides were not isolated from B*3507 molecules purified from the cell lines expressing this subtype, whereas small amounts of the human mH peptides were isolated from B*3502 and B*3508 molecules purified from the cell lines expressing the subtypes. These results indicate that failure of the CTL recognition of the cell line carrying B*3507 is due to a lack of human mH antigens in this cell line. The failure of the CTL recognition of the cell lines carrying B*3502 and B*3508 is not explained by only the amount of the human mH peptides binding to these B35 subtype molecules because the amount of the human mH peptides eluted from B*3502 and B*3508 molecules purified from the cell lines carrying these B35 subtypes is almost the same as that eluted from B*3503 molecules purified from the cell lines carrying B*3503.(ABSTRACT TRUNCATED AT 400 WORDS)

Full Text

The Full Text of this article is available as a PDF (1.0 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Attaya M., Jameson S., Martinez C. K., Hermel E., Aldrich C., Forman J., Lindahl K. F., Bevan M. J., Monaco J. J. Ham-2 corrects the class I antigen-processing defect in RMA-S cells. Nature. 1992 Feb 13;355(6361):647–649. doi: 10.1038/355647a0. [DOI] [PubMed] [Google Scholar]
  2. Beck Y., Sekimata M., Nakayama S., Müller G. A., Müller C. A., Yamamoto J., Nagao T., Uchida H., Akiyama N., Kariyone A. Expression of human minor histocompatibility antigen on cultured kidney cells. Eur J Immunol. 1993 Feb;23(2):467–472. doi: 10.1002/eji.1830230225. [DOI] [PubMed] [Google Scholar]
  3. Biddison W. E., Kostyu D. D., Strominger J. L., Krangel M. S. Delineation of immunologically and biochemically distinct HLA-A2 antigens. J Immunol. 1982 Aug;129(2):730–734. [PubMed] [Google Scholar]
  4. Biddison W. E., Ward F. E., Shearer G. M., Shaw S. The self determinants recognized by human virus-immune T cells can be distinguished from the serologically defined HLA antigens. J Immunol. 1980 Feb;124(2):548–552. [PubMed] [Google Scholar]
  5. Bjorkman P. J., Saper M. A., Samraoui B., Bennett W. S., Strominger J. L., Wiley D. C. Structure of the human class I histocompatibility antigen, HLA-A2. Nature. 1987 Oct 8;329(6139):506–512. doi: 10.1038/329506a0. [DOI] [PubMed] [Google Scholar]
  6. Bodmer J. G., Marsh S. G., Albert E. D., Bodmer W. F., Dupont B., Erlich H. A., Mach B., Mayr W. R., Parham P., Sasazuki T. Nomenclature for factors of the HLA system, 1991. WHO Nomenclature Committee for factors of the HLA system. Tissue Antigens. 1992 Apr;39(4):161–173. doi: 10.1111/j.1399-0039.1992.tb01932.x. [DOI] [PubMed] [Google Scholar]
  7. Chertkoff L. P., Herrera M., Fainboim L., Satz M. L. Complete nucleotide sequence of a genomic clone encoding HLA-B35 isolated from a Caucasian individual of Hispanic origin. Identification of a new variant of HLA-B35. Hum Immunol. 1991 Jul;31(3):153–158. doi: 10.1016/0198-8859(91)90020-a. [DOI] [PubMed] [Google Scholar]
  8. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  9. Cowan E. P., Jelachich M. L., Coligan J. E., Biddison W. E. Site-directed mutagenesis of an HLA-A3 gene identifies amino acid 152 as crucial for major-histocompatibility-complex-restricted and alloreactive cytotoxic-T-lymphocyte recognition. Proc Natl Acad Sci U S A. 1987 Jul;84(14):5014–5018. doi: 10.1073/pnas.84.14.5014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cowan E. P., Jordan B. R., Coligan J. E. Molecular cloning and DNA sequence analysis of genes encoding cytotoxic T lymphocyte-defined HLA-A3 subtypes: the E1 subtype. J Immunol. 1985 Oct;135(4):2835–2841. [PubMed] [Google Scholar]
  11. Falk K., Rötzschke O., Rammensee H. G. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature. 1990 Nov 15;348(6298):248–251. doi: 10.1038/348248a0. [DOI] [PubMed] [Google Scholar]
  12. Gaston J. S., Rickinson A. B., Epstein M. A. Epstein-Barr virus-specific cytotoxic T lymphocytes as probes of HLA polymorphism. Heterogeneity of T cell-restricting determinants associated with the serologically defined HLA-A2 antigen. J Exp Med. 1983 Aug 1;158(2):280–293. doi: 10.1084/jem.158.2.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Goulmy E., Gratama J. W., Blokland E., Zwaan F. E., van Rood J. J. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature. 1983 Mar 10;302(5904):159–161. doi: 10.1038/302159a0. [DOI] [PubMed] [Google Scholar]
  14. Goulmy E., van Leeuwen A., Blokland E., van Rood J. J., Biddison W. E. Major histocompatibility complex-restricted H-Y-specific antibodies and cytotoxic T lymphocytes may recognize different self determinants. J Exp Med. 1982 May 1;155(5):1567–1572. doi: 10.1084/jem.155.5.1567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hayashi H., Ennis P. D., Ariga H., Salter R. D., Parham P., Kano K., Takiguchi M. HLA-B51 and HLA-Bw52 differ by only two amino acids which are in the helical region of the alpha 1 domain. J Immunol. 1989 Jan 1;142(1):306–311. [PubMed] [Google Scholar]
  16. Haynes B. F., Reisner E. G., Hemler M. E., Strominger J. L., Eisenbarth G. S. Description of monoclonal antibody defining an HLA allotypic determinant that includes specificities within the B5 cross-reacting group. Hum Immunol. 1982 Jul;4(4):273–285. doi: 10.1016/0198-8859(82)90001-5. [DOI] [PubMed] [Google Scholar]
  17. Hogan K. T., Shimojo N., Walk S. F., Engelhard V. H., Maloy W. L., Coligan J. E., Biddison W. E. Mutations in the alpha 2 helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide. J Exp Med. 1988 Aug 1;168(2):725–736. doi: 10.1084/jem.168.2.725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Irle C., Beatty P. G., Mickelson E., Thomas E. D., Hansen J. A. Alloreactive T cell responses between HLA-identical siblings. Detection of anti-minor histocompatibility T cell clones induced in vivo. Transplantation. 1985 Sep;40(3):329–333. doi: 10.1097/00007890-198509000-00021. [DOI] [PubMed] [Google Scholar]
  19. Kelly A., Powis S. H., Kerr L. A., Mockridge I., Elliott T., Bastin J., Uchanska-Ziegler B., Ziegler A., Trowsdale J., Townsend A. Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature. 1992 Feb 13;355(6361):641–644. doi: 10.1038/355641a0. [DOI] [PubMed] [Google Scholar]
  20. Little A. M., Parham P. The HLA-Bw75 subtype of B15: molecular characterization and comparison with crossreacting antigens. Tissue Antigens. 1991 Oct;38(4):186–190. doi: 10.1111/j.1399-0039.1991.tb01895.x. [DOI] [PubMed] [Google Scholar]
  21. Nuchtern J. G., Bonifacino J. S., Biddison W. E., Klausner R. D. Brefeldin A implicates egress from endoplasmic reticulum in class I restricted antigen presentation. Nature. 1989 May 18;339(6221):223–226. doi: 10.1038/339223a0. [DOI] [PubMed] [Google Scholar]
  22. Ooba T., Hayashi H., Karaki S., Tanabe M., Kano K., Takiguchi M. The structure of HLA-B35 suggests that it is derived from HLA-Bw58 by two genetic mechanisms. Immunogenetics. 1989;30(2):76–80. doi: 10.1007/BF02421534. [DOI] [PubMed] [Google Scholar]
  23. Radka S. F., Kostyu D. D., Amos D. B. A monoclonal antibody directed against the HLA-Bw6 epitope. J Immunol. 1982 Jun;128(6):2804–2806. [PubMed] [Google Scholar]
  24. Rötzschke O., Falk K., Wallny H. J., Faath S., Rammensee H. G. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science. 1990 Jul 20;249(4966):283–287. doi: 10.1126/science.1695760. [DOI] [PubMed] [Google Scholar]
  25. Saper M. A., Bjorkman P. J., Wiley D. C. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution. J Mol Biol. 1991 May 20;219(2):277–319. doi: 10.1016/0022-2836(91)90567-p. [DOI] [PubMed] [Google Scholar]
  26. Sekimata M., Griem P., Egawa K., Rammensee H. G., Takiguchi M. Isolation of human minor histocompatibility peptides. Int Immunol. 1992 Feb;4(2):301–304. doi: 10.1093/intimm/4.2.301. [DOI] [PubMed] [Google Scholar]
  27. Sood A. K., Pereira D., Weissman S. M. Isolation and partial nucleotide sequence of a cDNA clone for human histocompatibility antigen HLA-B by use of an oligodeoxynucleotide primer. Proc Natl Acad Sci U S A. 1981 Jan;78(1):616–620. doi: 10.1073/pnas.78.1.616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Spies T., Cerundolo V., Colonna M., Cresswell P., Townsend A., DeMars R. Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature. 1992 Feb 13;355(6361):644–646. doi: 10.1038/355644a0. [DOI] [PubMed] [Google Scholar]
  29. Spies T., DeMars R. Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter. Nature. 1991 May 23;351(6324):323–324. doi: 10.1038/351323a0. [DOI] [PubMed] [Google Scholar]
  30. Takiguchi M., Kawaguchi G., Sekimata M., Hiraiwa M., Kariyone A., Takamiya Y. The role of the conserved residue in pocket A and the polymorphic residue in pocket E of HLA-B*3501 in presentation of human minor histocompatibility peptides to T cells. Int Immunol. 1994 Sep;6(9):1345–1352. doi: 10.1093/intimm/6.9.1345. [DOI] [PubMed] [Google Scholar]
  31. Tekolf W. A., Shaw S. Primary in vitro generation of cytotoxic cells specific for human minor histocompatibility antigens between HLA-identical siblings. J Immunol. 1984 Apr;132(4):1756–1760. [PubMed] [Google Scholar]
  32. Theiler G., Pando M., Delfino J. M., Takiguchi M., Satz M. L. Isolation and characterization of two new functional subtypes of HLA-B35. Tissue Antigens. 1993 Mar;41(3):143–147. doi: 10.1111/j.1399-0039.1993.tb01993.x. [DOI] [PubMed] [Google Scholar]
  33. Townsend A., Elliott T., Cerundolo V., Foster L., Barber B., Tse A. Assembly of MHC class I molecules analyzed in vitro. Cell. 1990 Jul 27;62(2):285–295. doi: 10.1016/0092-8674(90)90366-m. [DOI] [PubMed] [Google Scholar]
  34. Townsend A., Ohlén C., Bastin J., Ljunggren H. G., Foster L., Kärre K. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature. 1989 Aug 10;340(6233):443–448. doi: 10.1038/340443a0. [DOI] [PubMed] [Google Scholar]
  35. Wallny H. J., Rammensee H. G. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature. 1990 Jan 18;343(6255):275–278. doi: 10.1038/343275a0. [DOI] [PubMed] [Google Scholar]
  36. Yamamoto J., Kariyone A., Akiyama N., Kano K., Takiguchi M. Presentation of human minor histocompatibility antigens by HLA-B35 and HLA-B38 molecules. Proc Natl Acad Sci U S A. 1990 Apr;87(7):2583–2587. doi: 10.1073/pnas.87.7.2583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Yewdell J. W., Bennink J. R. Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes. Science. 1989 Jun 2;244(4908):1072–1075. doi: 10.1126/science.2471266. [DOI] [PubMed] [Google Scholar]
  38. Zemmour J., Little A. M., Schendel D. J., Parham P. The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J Immunol. 1992 Mar 15;148(6):1941–1948. [PubMed] [Google Scholar]
  39. Zier K. S., Elkins W. L., Pierson G. R. Cytotoxic T lymphocyte lines (CTLL) against a human minor alloantigen. Immunogenetics. 1982;15(5):501–508. doi: 10.1007/BF00345909. [DOI] [PubMed] [Google Scholar]
  40. de Bueger M., Verreck F., Blokland E., Drijfhout J. W., Amons R., Koning F., Goulmy E. Isolation of an HLA-A2.1 extracted human minor histocompatibility peptide. Eur J Immunol. 1993 Mar;23(3):614–618. doi: 10.1002/eji.1830230305. [DOI] [PubMed] [Google Scholar]
  41. van Els C. A., D'Amaro J., Pool J., Blokland E., Bakker A., van Elsen P. J., van Rood J. J., Goulmy E. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenetics. 1992;35(3):161–165. doi: 10.1007/BF00185109. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES